Measles resurgence: an antiviral under study

Measles outbreak resurgence: an antiviral drug under investigation

July 31, 2026

By Nicolas Gutierrez C. THE Subscribers

Measles is making a strong comeback worldwide due to a significant drop in vaccination rates. This antiviral drug would help protect infected individuals and reduce their contagiousness.

The measles epidemic in the United States is the largest in 35 years.

The measles epidemic (measles) in the United States is the largest in 35 years.

Photo by JAN SONNENMAIR / GETTY IMAGES NORTH AMERICA / GETTY IMAGES VIA AFP

Measles cases continue to rise and the situation is sure to worsen. The cause is the decline in vaccination rates, which is responsible for the largest measles outbreak in the United States In 35 years: by 2026, there had already been 2,318 cases in just seven months, exceeding the total for 2025 (2,289). This upward trend is also found in France and across the globe, largely due to the rise of VaccinoscepticismTo such an extent that experts are beginning to look for alternatives to vaccination to reduce the number of cases and lessen the severity of the disease in infected individuals. Researchers at Georgia State University in the United States have just presented one such alternative: an antiviral that could be administered even after infection and that would significantly reduce the contagiousness of infected individuals, while protecting their health. Their results were published on July 24, 2026 in Nature Microbiology.

Blocking the virus's life cycle to stop the infection

Measles Antiviral Infection Epidemic

en_USEnglish